BATF and metabolic dysfunction-associated steatohepatitis: Nonetheless, our findings prompt us to consider the possibility that the adoptive transfer of Tregs expanded ex vivo, targeting the Nr4a/Batf axis, may hold therapeutic promise against MASH.